Valuation: Personalis, Inc.

Market Cap 1.48B 1.28B 1.2B 1.09B 2.06B 142B 2.09B 14.08B 5.52B 71.06B 5.57B 5.45B 236B P/E 2026 *
-12.7x
P/E 2027 * -14.8x
Enterprise Value 1.31B 1.13B 1.06B 963M 1.81B 125B 1.84B 12.4B 4.86B 62.55B 4.9B 4.8B 208B EV / Sales 2026 *
15.8x
EV / Sales 2027 * 12.7x
Free-Float
73.85%
Yield 2026 *
-
Yield 2027 * -
1 day-1.07%
1 week-4.21%
Current month+9.72%
1 month-9.75%
3 months+118.40%
6 months+62.08%
Current year+74.50%
1 week 13.78
Extreme 13.782
14.51
1 month 11.52
Extreme 11.52
14.81
Current year 4.96
Extreme 4.955
16.39
1 year 4.44
Extreme 4.44
16.39
3 years 0.89
Extreme 0.8906
16.39
5 years 0.89
Extreme 0.8906
23.04
10 years 0.89
Extreme 0.8906
53.46
Manager TitleAgeSince
Chief Executive Officer 57 2023-03-01
Chief Executive Officer 65 2022-12-30
President 55 2026-03-12
Director TitleAgeSince
Director/Board Member 79 2019-04-30
Chairman 76 2022-05-16
Director/Board Member 72 2021-03-05
Date Insider Type Main position Quantity % Market Cap.
7/15/26 Fiscal year

Chairperson

300,000 0.2865%
7/9/26 Fiscal year

Chief Executive Officer

300,000 0.2865%
6/29/26 Fiscal year

Chief Financial Officer

14,946 0.0143%
Change 5-day change 1-year change 3-year change Capi.($)
-1.07%-4.21%+201.96%+689.20% 1.48B
+0.68%-2.28%+2.16%+19.70% 48.84B
+4.07%+2.43%+483.70%+623.80% 45.44B
+4.33%+0.98%+12.80%+88.53% 41.22B
+1.94%-0.31%+26.24%+12.62% 39.71B
-0.50%0.00%+20.60%+60.49% 32.6B
-0.44%-3.22% - - 16.25B
+3.22%-0.88%+30.42%+135.47% 16.67B
-0.62%-0.06%+3.46%+27.74% 14.08B
+2.35%+3.48%+82.95%+43.41% 13.68B
Average +1.40%-0.41%+96.03%+189.00% 27B
Weighted average by Cap. +1.95%+0.00%+103.72%+156.45%

Financials

2026 *2027 *
Net sales 82.47M 71.19M 66.79M 60.83M 114M 7.88B 116M 783M 307M 3.95B 310M 303M 13.14B 109M 94.52M 88.67M 80.77M 152M 10.47B 154M 1.04B 407M 5.24B 411M 402M 17.45B
Net income -115M -99.36M -93.22M -84.9M -160M -11B -162M -1.09B -428M -5.51B -432M -423M -18.34B -102M -88.01M -82.57M -75.21M -141M -9.75B -143M -968M -379M -4.88B -383M -374M -16.25B
Net Debt -178M -153M -144M -131M -246M -16.98B -250M -1.69B -661M -8.51B -667M -652M -28.3B -91.04M -78.59M -73.73M -67.16M -126M -8.7B -128M -864M -339M -4.36B -342M -334M -14.51B
Logo Personalis, Inc.
Personalis, Inc. is engaged in developing, marketing and selling advanced cancer genomic tests and analytics. The Company’s advanced genomic sequencing and analytics support the development of personalized cancer vaccines and other cancer immunotherapies. Its products include NeXT Personal, ImmunoI DNeXT, NeXT Personal Dx, NeXT Dx, whole exome sequencing (WES), and whole genome sequencing (WGS). NeXT Personal is a tumor-informed liquid biopsy test for the detection of minimal residual disease (MRD) and recurrence in cancer. NeXT Dx is a comprehensive tumor profiling test that is used to help select therapy for a cancer patient and identify potential clinical trials for a patient. The Company performed WGS on human samples for research projects, such as population sequencing initiatives. The Company’s tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and the development of personalized cancer therapies.
Employees
260
Date Price Change Volume
26-08-17 US$13.89 -1.07% 1,093,925
26-08-14 US$14.04 -2.64% 1,042,770
26-08-13 US$14.42 +1.48% 1,168,973
26-08-12 US$14.21 +1.36% 1,549,807
26-08-11 US$14.02 -3.31% 3,233,087
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
13.89USD
Average target price
13.88USD
Spread / Average Target
-0.11%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. PSNL Stock